GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market

Phase III Study Misses Endpoint

The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.

new gsk logo and hq
DREAMM-3's failure does not bode well for further readouts in earlier myeloma therapy, and could even see Blenrep removed from the market. • Source: GSK

GSK’s efforts to build a presence in the multiple myeloma market with Blenrep (belantamab mafodotin) have suffered a major setback, after it failed to improve on standard second-line therapy in a confirmatory Phase III study.

The BCMA-targeted antibody-drug conjugate failed to meet its primary endpoint of improved progression-free survival (PFS) compared with Celgene’s Pomalyst...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By 

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By 

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

More from R&D

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By 

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.